Inventor · disambiguated record
Adam Clarke
Also filed as: CLARKE ADAM · CLARKE ADAM W · CLARKE ADAM WILLIAM
24 granted patents·15 pending applications·87 citations·filing 2006–2025
95Inventor score
Files withTEVA PHARMACEUTICALS AUSTRALIA PTY LTD16CEPHALON LLC9CEPHALON INC5CLARKE ADAM WILLIAM2ARANA THERAPEUTICS LTD1
Top patents by PatentIndex Score
39 records- 0195US10138296B2Antibodies that specifically bind to TL1ACEPHALON INC·Filed 2016·Granted Nov 27, 2018·17 cites·34 claims
- 0293US11220549B2Antibodies that specifically bind to TL1A and methods of treating respiratory tract diseasesCEPHALON INC·Filed 2018·Granted Jan 11, 2022·8 cites·31 claims
- 0390US10822422B2Antibodies against TL1a and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Granted Nov 3, 2020·10 cites·13 claims
- 0489US11725052B2Anti-PAR-2 antibodies and methods of use thereofCEPHALON LLC·Filed 2021·Granted Aug 15, 2023·2 cites·26 claims
- 0587US9963515B2Anti-CD38 antibodies and fusions to attenuated interferon alpha-2BTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2015·Granted May 8, 2018·5 cites·27 claims
- 0687US9611322B2Fusions of antibodies to CD38 and attenuated interferon alphaTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Granted Apr 4, 2017·6 cites·18 claims
- 0787US2025353919A1Antibodies Against TL1A and Uses ThereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2025·Application pending·0 cites
- 0886US10544199B2Interferon alpha 2B variantsTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2015·Granted Jan 28, 2020·7 cites·20 claims
- 0985US11267883B2Antibodies that specifically bind to human IL-15 and uses thereofCEPHALON INC·Filed 2017·Granted Mar 8, 2022·5 cites·27 claims
- 1085US8563697B2Anti-IL-12/IL-23 antibodiesCLARKE ADAM WILLIAM·Filed 2009·Granted Oct 22, 2013·11 cites·11 claims
- 1184US2025179202A1Antibodies That Specifically Bind to TL1A and Methods of Treating Skin DiseaseCEPHALON LLC·Filed 2024·Application pending·0 cites
- 1283US12410256B2Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseasesTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2023·Granted Sep 9, 2025·0 cites·19 claims
- 1383US11319356B2Interferon alpha 2B variantsTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2019·Granted May 3, 2022·2 cites·18 claims
- 1483US10981986B2Fusions of antibodies to CD38 and attenuated interferon alphaTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2017·Granted Apr 20, 2021·2 cites·21 claims
- 1582US11111292B2Anti-IL-5 antibodiesCEPHALON INC·Filed 2017·Granted Sep 7, 2021·3 cites·24 claims
- 1682US10906973B2Antibody variants transmigrating the blood-brain barrier and uses thereofNAT RES COUNCIL CANADA·Filed 2017·Granted Feb 2, 2021·3 cites·19 claims
- 1778US2024301076A1Anti-cxcr2 antibodies and uses thereofCEPHALON LLC·Filed 2024·Application pending·0 cites
- 1877US12384841B2Anti-PAR-2 antibodies and methods of use thereofCEPHALON LLC·Filed 2023·Granted Aug 12, 2025·0 cites·3 claims
- 1977US12162946B2Antibodies that specifically bind to TL1A and methods of treating gastrointestinal diseaseCEPHALON LLC·Filed 2021·Granted Dec 10, 2024·0 cites·31 claims
- 2075US11332534B2Anti-CXCR2 antibodies and uses thereofCEPHALON INC·Filed 2019·Granted May 17, 2022·1 cites·13 claims
- 2175US11117975B2Anti-CD38 antibodies and fusions to attenuated interferon alpha-2BTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2018·Granted Sep 14, 2021·1 cites·13 claims
- 2273US12018084B2Anti-CXCR2 antibodies and uses thereofCEPHALON LLC·Filed 2022·Granted Jun 25, 2024·0 cites·25 claims
- 2371US12410247B2Polynucleotides encoding antibodies that specifically bind to human IL-15CEPHALON LLC·Filed 2022·Granted Sep 9, 2025·0 cites·20 claims
- 2469US9127057B2Anti-IL-23 heterodimer specific antibodiesCLARKE ADAM WILLIAM·Filed 2011·Granted Sep 8, 2015·2 cites·16 claims
- 2569US8470320B2Humanised antibodies with anti-tumour activityCLARKE ADAM W·Filed 2010·Granted Jun 25, 2013·2 cites·50 claims
- 2669US2022220184A1Interferon alpha 2b variantsTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2022·Application pending·0 cites
- 2768US2021347904A1Antibodies against tl1a and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2020·Application pending·0 cites
- 2864US2014255302A1ANTIBODIES AGAINST TL1a AND USES THEREOFTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Application pending·0 cites
- 2961US12358980B2Compositions and methods for anti-PACAP antibodiesCEPHALON LLC·Filed 2022·Granted Jul 15, 2025·0 cites·20 claims
- 3060US2025122291A1Anti-trka antibodies and uses thereofCEPHALON LLC·Filed 2024·Application pending·0 cites
- 3158US2008255343A1Chimeric antibodiesARANA THERAPEUTICS LTD·Filed 2008·Application pending·0 cites
- 3254US8901279B2Humanized antibodies with anti-tumor activityTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2013·Granted Dec 2, 2014·0 cites·27 claims
- 3354US2008139790A1Chimeric antibodiesJENNINGS PHILIP A·Filed 2006·Application pending·0 cites
- 3454US2016367695A1Polypeptide constructs and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Application pending·0 cites
- 3552US2014086922A1Anti-il-12/il-23 antibodiesCEPHALON AUSTRALIA PTY LTD·Filed 2013·Application pending·0 cites
- 3650US2011319597A1Variant domain antibodiesSIMPSON RAINA JUI YU·Filed 2009·Application pending·0 cites
- 3747US2016264661A1Anti-il-12/il-23 antibodiesTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Application pending·0 cites
- 3845US2008095767A1Engineered antibodies with new world primate framework regionsPEPTECH LTD·Filed 2007·Application pending·0 cites
- 3942US2014286957A1ANTIBODIES TO CD1dTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Adam Clarke files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →